On February 25, 2020, the Securities and Exchange Commission ("SEC") announced the filing of its fourth quarter and full year 2019 financial results.  The SEC's complaint alleges that Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a biopharmaceutical company focused on developing kinase inhibitors for atopic dermatitis, failed to generate sufficient cash and investments to fund its clinical trials.  The SEC's complaint, filed in federal court in the District of Columbia, alleges that Aclaris violated the antifungal antifungal antifungal antibody registration provisions of the federal securities laws.  The SEC's complaint further alleges that Aclaris failed to adequately evaluate the safety and efficacy of ATI-450.  The SEC's complaint, filed in the U.S. District Court for the District of Columbia, charges Aclaris with violating the antifungal antifungal registration provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  Without admitting or denying the allegations in the SEC's complaint, Aclaris has consented to the entry of a final judgment that permanently enjoins it from violating the antifungal registration provisions of Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, and orders it to pay disgorgement of $5.5 million and $7.9 million, respectively.  The settlement is subject to court approval.  The SEC's complaint charges Aclaris with violating Section 17(a) of the Securities Act and Section 10(b) of the Exchange Act, Rule 10b-5 thereunder, and Sections 206(1), 206(2), and 206(4) of the Investment Advisers Act of 1940 ("Advisers Act") and Rule 206(4)-8 thereunder.  Without admitting or denying the SEC's allegations, Aclaris has agreed to the entry of a final judgment permanently enjoining it from future violations of the antifungal registration provisions of Sections 206(1) and 206(2) of the Investment Advisers Act and Rule 206(4)-8 thereunder, and ordering it to pay disgorgement of $13.6 million and $27.6 million, respectively, in 2019 and 2020.  The settlement is subject to Court approval.  The SEC's investigation was conducted by Lachlan Hanbury-Brown and Thomas Smith of the SEC's Philadelphia Regional Office.  The litigation will be led by Neal Walker.  The SEC appreciates the assistance of the U.S. Attorney's Office